Congenital Toxoplasmosis and Audiological Outcome: from a Case Series to a Suggestion of Patient-based Schedule

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2024 Jan 19

PMID 38239593

Authors

S Salome

R Malesci

V Delle Cave

A Amitrano

R Gammella

F Fanelli

E Capone

L Capasso

A R Fetoni

F Raimondi

Affiliations

Soon will be listed here.

Abstract

Introduction: Sensorineural hearing loss (SNHL) has been suggested to be possibly related to congenital toxoplasmosis (CT), although its prevalence varies from 0% to 26%. This variance appears to be dependent especially on early timing of treatment. However, the available data are based on outdated studies conducted on small groups of patients that lack homogeneity. Therefore, to establish evidence-based guidelines for audiologic monitoring in CT, we conducted a comprehensive evaluation of a large case series over a long period of time.

Patients And Methods: This is a single-center, retrospective cohort that enrolled all infants and children who were exposed to and/or congenitally infected between September 1980 and December 2022. They underwent standard serial audiological evaluations to detect possible SNHL at an early stage. The first evaluation was performed during the initial assessment to define the onset of congenital toxoplasmosis, with another evaluation conducted at least at 12 months of life.

Results: We collected data from 1,712 patients, and 183 (10.7%) were diagnosed with CT. Among these cases, 78 children (42.6%) presented with symptomatic CT at the onset, exhibiting ocular findings (21.1%), clinical cerebral manifestations (6.1%), and/or abnormal findings on neuroimaging (35.5%). Therapy was administrated at the onset in 164 patients (89.6%) with 115 of them starting treatment prior to 2.5 months of age (0-388, median 32.00 ± 92.352 days of life). Only one patient presented with SNHL at the onset, but this was apparently unrelated to CT. The median number of audiological assessments was 2.2 ± 1.543 (2-10). No patients developed any grade of delayed hearing loss, both in treated and untreated groups. The median age at last audiological evaluation was 2.3 ± 2.18 years (1-8), although the median follow-up period was 12.4 years (±6.3), ranging from 1 to 27 years.

Conclusions: Based on these data, it appears that SNHL may be less frequent in CT than previously assumed. We recommend conducting an audiological assessment at the onset (within the first 2.5 months of life) to comprehensively define the type of CT onset, and then conducting another evaluation within 9 months of life.

References

Freij B, Sever J . Toxoplasmosis. Pediatr Rev. 1991; 12(8):227-36. DOI: 10.1542/pir.12-8-227. View

McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N . Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006; 42(10):1383-94. DOI: 10.1086/501360. View

Beswick R, Driscoll C, Kei J . Monitoring for postnatal hearing loss using risk factors: a systematic literature review. Ear Hear. 2012; 33(6):745-56. DOI: 10.1097/AUD.0b013e31825b1cd9. View

Stagno S, Reynolds D, Amos C, Dahle A, McCollister F, Mohindra I . Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics. 1977; 59(5):669-78. View

McAuley J, Boyer K, Patel D, Mets M, Swisher C, Roizen N . Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis. 1994; 18(1):38-72. DOI: 10.1093/clinids/18.1.38. View

Salviz M, Montoya J, Nadol J, Santos F . Otopathology in congenital toxoplasmosis. Otol Neurotol. 2013; 34(6):1165-9. PMC: 3713185. DOI: 10.1097/MAO.0b013e31828297b6. View

Khan K, Khan W . Congenital toxoplasmosis: An overview of the neurological and ocular manifestations. Parasitol Int. 2018; 67(6):715-721. DOI: 10.1016/j.parint.2018.07.004. View

Alday P, Doggett J . Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther. 2017; 11:273-293. PMC: 5279849. DOI: 10.2147/DDDT.S60973. View

Bower C, Reilly B, Richerson J, Hecht J . Hearing Assessment in Infants, Children, and Adolescents: Recommendations Beyond Neonatal Screening. Pediatrics. 2023; 152(3). DOI: 10.1542/peds.2023-063288. View

10.

McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H . Why prevent, diagnose and treat congenital toxoplasmosis?. Mem Inst Oswaldo Cruz. 2009; 104(2):320-44. PMC: 2735102. DOI: 10.1590/s0074-02762009000200029. View

11.

Lebech M, Joynson D, Seitz H, Thulliez P, Gilbert R, Dutton G . Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis. Eur J Clin Microbiol Infect Dis. 1996; 15(10):799-805. DOI: 10.1007/BF01701522. View

12.

Auriti C, Bucci S, De Rose D, Coltella L, Santisi A, Martini L . Maternal-Fetal Infections (Cytomegalovirus, , Syphilis): Short-Term and Long-Term Neurodevelopmental Outcomes in Children Infected and Uninfected at Birth. Pathogens. 2022; 11(11). PMC: 9692284. DOI: 10.3390/pathogens11111278. View

13.

Cortina-Borja M, Tan H, Wallon M, Paul M, Prusa A, Buffolano W . Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med. 2010; 7(10). PMC: 2953528. DOI: 10.1371/journal.pmed.1000351. View

14.

Nobrega M, Weckx L, Juliano Y . Study of the hearing loss in children and adolescents, comparing the periods of 1990-1994 and 1994-2000. Int J Pediatr Otorhinolaryngol. 2005; 69(6):829-38. DOI: 10.1016/j.ijporl.2005.01.019. View

15.

Fontes A, Carvalho S, Andrade G, Carellos E, Romanelli R, Macedo de Resende L . Study of brainstem auditory evoked potentials in early diagnosis of congenital toxoplasmosis. Braz J Otorhinolaryngol. 2018; 85(4):447-455. PMC: 9443022. DOI: 10.1016/j.bjorl.2018.03.012. View

16.

Salome S, Grieco C, Barra P, Capone E, Grasso F, Carraturo F . Specific antibody titer decay in neonates prenatally exposed to Toxoplasma gondii and their mothers. Ital J Pediatr. 2022; 48(1):63. PMC: 9066792. DOI: 10.1186/s13052-022-01261-2. View

17.

Brown E, Chau J, Atashband S, Westerberg B, Kozak F . A systematic review of neonatal toxoplasmosis exposure and sensorineural hearing loss. Int J Pediatr Otorhinolaryngol. 2009; 73(5):707-11. DOI: 10.1016/j.ijporl.2009.01.012. View

18.

Austeng M, Eskild A, Jacobsen M, Jenum P, Whitelaw A, Engdahl B . Maternal infection with toxoplasma gondii in pregnancy and the risk of hearing loss in the offspring. Int J Audiol. 2010; 49(1):65-8. DOI: 10.3109/14992020903214053. View

19.

Bollani L, Auriti C, Achille C, Garofoli F, De Rose D, Meroni V . Congenital Toxoplasmosis: The State of the Art. Front Pediatr. 2022; 10:894573. PMC: 9301253. DOI: 10.3389/fped.2022.894573. View

20.

Wilson C, Remington J, Stagno S, Reynolds D . Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980; 66(5):767-74. View